...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles
【24h】

Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles

机译:1-取代的2-苄基-5-硝基吲唑啉-3-酮和3-烷氧基-2-苄基-5-硝基-2H-吲唑的抗chachaic和滴虫酸活性

获取原文
获取原文并翻译 | 示例
           

摘要

Two series of new 5-nitroindazole derivatives, 1-substituted 2-benzylindazolin-3-ones (6-29, series A) and 3-alkoxy-2-benzyl-2H-indazoles (30-37, series B), containing differently functionalized chains at position 1 and 3, respectively, have been synthesized starting from 2-benzyl-5-nitroindazolin-3-one 5, and evaluated against the protozoan parasites Trypanosoma cruzi and Trichomonas vaginalis, etiological agents of Chagas disease and trichomonosis, respectively. Many indazolinones of series A were efficient against different morphological forms of T cruzi CL Brener strain (compounds 6, 7, 9, 10 and 19-21: IC50 = 1.58-4.19 mu M for epimastigotes; compounds 6, 19-21 and 24: IC50 = 0.22-0.54 mu M for amastigotes) being as potent as the reference drug benznidazole. SAR analysis suggests that electron-donating groups at position 1 of indazolinone ring are associated with an improved antichagasic activity. Moreover, compounds of series A displayed low unspecific toxicities against an in vitro model of mammalian cells (fibroblasts), which were reflected in high values of the selectivity indexes (SI). Compound 20 was also very efficient against amastigotes from Tulahuen and Y strains of T cruzi (IC50 = 0.81 and 0.60 mu M, respectively), showing low toxicity towards cardiac cells (LC50 > 100 mu M). In what concerns compounds of series B, some of them displayed moderate activity against trophozoites of a metronidazole-sensitive isolate of T vaginalis (35 and 36: IC50 = 9.82 and 7.25 mu M, respectively), with low unspecific toxicity towards Vero cells. Compound 36 was also active against a metronidazole-resistant isolate (1050 = 9.11 mu M) and can thus be considered a good prototype for the development of drugs directed to T vaginalis resistant to 5-nitroimidazoles. (C) 2016 Elsevier Masson SAS. All rights reserved.
机译:两套新的5-硝基吲唑衍生物,分别是1-取代的2-苄基吲唑啉-3-酮(6-29,A系列)和3-烷氧基-2-苄基-2H-吲唑(30-37,B系列)从2-苄基-5-硝基吲唑啉-3-one 5开始分别合成了位置1和位置3的功能化链,并分别针对原生动物寄生虫克氏锥虫和阴道毛滴虫,Chagas病和滴虫病的病原体进行了评估。许多系列A的吲唑啉酮均有效对抗不同形态的T cruzi CL Brener菌株(化合物6、7、9、10和19-21:表皮鞭虫的IC50 = 1.58-4.19μM;化合物6、19-21和24: IC50 = 0.22-0.54μM(对于amastigotes而言)与参考药物苯硝唑一样有效。 SAR分析表明,吲唑啉酮环第1位的给电子基团具有改善的抗chagasic活性。此外,A系列化合物对哺乳动物细胞(成纤维细胞)的体外模型显示出较低的非特异性毒性,这在较高的选择性指数(SI)中得到了体现。化合物20对来自图拉胡恩和图克鲁兹Y菌株的沙门氏菌也非常有效(分别为IC50 = 0.81和0.60μM),对心肌细胞毒性低(LC50> 100μM)。关于B系列化合物,其中一些对甲硝唑敏感的T阴道分离株的滋养体显示中等活性(分别为35和36:IC50 = 9.82和7.25μM),对Vero细胞的毒性较低。化合物36对甲硝唑耐药菌株也具有活性(1050 = 9.11μM),因此可以认为是开发针对对5-硝基咪唑具有抗性的T阴道杆菌的药物的良好原型。 (C)2016 Elsevier Masson SAS。版权所有。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号